

## Titanium Implants with Enhanced Cell Integration and Antimicrobial Properties

**Track Code:** 2022-RAHI-69768

**Categories:**

- Biomedical Engineering

**Keywords:**

- Biomedical Engineering
- Nanotexturing
- Osteoinductive
- Silver nanoparticles

Researchers at Purdue University have developed a new method to manufacture antimicrobial, cell-integrated implants. Despite the great advancement and wide use of titanium (Ti) and Ti-based alloys in different orthopedic implants, device-related infections remain the major complication in orthopedic and trauma surgery. Most of these infections are often caused by both poor antibacterial and osteoinductive properties of the implant surface. The Purdue researchers' process is a two-step laser nanotexturing (LN) and immobilization (LI) method of coating silver onto titanium implants. LN increases cell integration, and LI reduces the toxicity of silver nanoparticles to surrounding cells. Use of this method causes implants to better-integrate into the body and be toxic to bacteria but not cells, and ultimately reduce chances of bacterial infection.

**Technology Validation:** The researchers' nanotexturing method caused a 2.5-fold increase in osseointegration compared to pristine Ti surface. In testing with gram-positive and gram-negative bacteria, the LN-Ti/LI-Ag surface was observed to have efficient and stable antimicrobial properties for over six days yet has similar cytotoxicity to LN-Ti.

**Advantages:**

- Increases cell integration compared to pristine Ti implants- Antimicrobial properties
- Not toxic for animal cells

**Applications:**

- Titanium implants

**People:**

- Rahimi, Rahim (Project leader)
- Selvamani, Vidhya

**Intellectual Property:**

**Application Date:** December 31, 2022

**Type:** Utility Patent

**Country of Filing:** United States

**Patent Number:** (None)

**Issue Date:** (None)

**Application Date:** February 25, 2022

**Type:** Provisional-Patent

**Country of Filing:** United States

**Patent Number:** (None)

**Issue Date:** (None)

**Contact OTC:**

Purdue Office of Technology Commercialization

The Convergence Center

101 Foundry Drive, Suite 2500

West Lafayette, IN 47906

Phone: (765) 588-3475

Fax: (765) 463-3486

Email: [otcip@prf.org](mailto:otcip@prf.org)